Iain Cai

Biocytogen Pharmaceuticals

Contact Me

Biocytogen focuses on the discovery of monoclonal, bispecific, TCR-mimic antibodies and bispecific antibody-drug conjugates (ADCs) using its proprietary fully human antibody RenMice platform and high-throughput in vivo screening. Founded in 2009, Biocytogen has established a pipeline of 12 immuno-oncology assets, including two assets in Phase II, two in Phase I, and five in the CMC stage. Eucure Biopharma is the wholly owned subsidiary of Biocytogen dedicating to the clinical development of those innovative biological drugs.
Tuesday, March 14

7:30am PDT

8:15am PDT

8:30am PDT

9:00am PDT

9:45am PDT

10:30am PDT

11:00am PDT

11:30am PDT

12:15pm PDT

1:30pm PDT

2:00pm PDT

3:15pm PDT

3:30pm PDT

4:00pm PDT

4:45pm PDT

5:45pm PDT

6:00pm PDT

Wednesday, March 15

8:30am PDT

9:15am PDT

9:30am PDT

10:15am PDT

11:00am PDT

11:30am PDT

12:00pm PDT

1:00pm PDT

1:45pm PDT

2:15pm PDT

3:00pm PDT